UroGen Pharma Ltd. — Director's Dealing 2019

Mar 7, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-02-14

Reporting Person: Mullennix Stephen (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-14	Ordinary Shares	M	7034	—	Acquired	7034	Direct
2019-02-14	Ordinary Shares	S	2804	$37.30	Disposed	4230	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-14	Restricted Stock Units	$	M	7034	Disposed		Ordinary Shares (7034)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.

F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

F3: The reporting person was granted restricted stock units ("RSUs") on March 7, 2018, June 4, 2018 and October 28, 2018 representing 21,107 ordinary shares in the aggregate. 1/3rd of the RSUs vested on February 14, 2019 (with the issuance of the underlying ordinary shares delayed until March 5, 2019), with the balance vesting in equal quarterly installments thereafter over a period of two years.